Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $296,661.86 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 3,203 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $92.62, for a total value of $296,661.86. Following the transaction, the insider now directly owns 18,270 shares of the company’s stock, valued at approximately $1,692,167.40. This represents a 14.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Ariel Hurley also recently made the following trade(s):

• On Monday, January 13th, Ariel Hurley sold 2,250 shares of Blueprint Medicines stock. The shares were sold at an average price of $100.00, for a total value of $225,000.00.
• On Thursday, December 12th, Ariel Hurley sold 1,819 shares of Blueprint Medicines stock. The shares were sold at an average price of $93.26, for a total value of $169,639.94.

Blueprint Medicines Price Performance

Blueprint Medicines stock opened at $89.92 on Thursday. Blueprint Medicines Co. has a 12 month low of $80.68 and a 12 month high of $121.90. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The business has a 50 day simple moving average of $99.50 and a 200-day simple moving average of $94.34. The stock has a market capitalization of $5.75 billion, a PE ratio of -83.26 and a beta of 0.62.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Equities analysts predict that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Quarry LP purchased a new position in Blueprint Medicines in the third quarter worth $32,000. R Squared Ltd purchased a new position in Blueprint Medicines in the fourth quarter worth $51,000. Covestor Ltd grew its holdings in Blueprint Medicines by 206.7% in the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 403 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Blueprint Medicines in the fourth quarter valued at $65,000. Finally, Thematics Asset Management acquired a new position in shares of Blueprint Medicines during the 4th quarter worth $72,000.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on BPMC shares. StockNews.com downgraded Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Monday. JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $133.00 price target on shares of Blueprint Medicines in a report on Thursday, February 13th. Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 14th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $123.83.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.